We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Split on Cruciality of Clinical Tests for Biosimilarity
Drugmakers Split on Cruciality of Clinical Tests for Biosimilarity
April 24, 2012
Drugmakers commenting on the FDA’s trio of biosimilars guidance documents are split on the need for certain clinical tests as part of the agency’s stepwise approach to showing biosimilarity.